Outlook Therapeutics Announces $ 10 Million Common Stock Offer | 2021-11-23 | Press Releases

ISELIN, NJ, November 23, 2021 (GLOBE NEWSWIRE) – Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics & CloseCurlyDoubleQuote;), an advanced clinical biopharmaceutical company working on the development of the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that it has concluded a subscription agreement with HC Wainwright & Co., LLC under which the subscriber has agreed to purchase on a firm commitment basis 8,000,000 ordinary shares of Outlook Therapeutics, at a public price of 1, $ 25 per share, less subscription discounts and commissions. The offer is expected to close on or around November 29, 2021, subject to the satisfaction of customary closing conditions.

HC Wainwright & Co. acts as the sole accounting manager of the offering.

Outlook Therapeutics also granted the underwriter a 30-day option to purchase up to 1,200,000 additional common shares at the public offering price, less subscription discounts and commissions. The gross proceeds of Outlook Therapeutics, before deducting underwriting discounts and commissions and offering costs and assuming that no exercise of the underwriter’s option to purchase additional common shares, is expected to be approximately $ 10. , 0 million dollars.

Outlook Therapeutics intends to use the net proceeds of the offering for working capital and general corporate purposes, including to support its ONS-5010 development program.

Common shares are being offered by Outlook Therapeutics in accordance with a registration statement on Form S-3 (File No. 333-254778) originally filed with the Securities and Exchange Commission (the “SEC & CloseCurlyDoubleQuote”) on March 26, 2021 and declared effective by the SEC on April 1, 2021. The offering of the Common Shares is made only by way of a prospectus, including a prospectus supplement, which forms part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the Offer and describing the terms of the Offer will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus and the final prospectus supplement and accompanying prospectus may also be obtained, when available, by contacting HC Wainwright & Co., LLC at 430 Park Avenue , 3rd Floor, New York, NY 10022, by calling (212) 856-5711 or emailing [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy such securities, and there will be no sale of such securities in any State or other jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working on the development and launch of ONS-5010 / LYTENAVA ™ (bevacizumab-vikg) as the first ophthalmic formulation of bevacizumab approved by the FDA for use in retinal indications, including wet AMD , the DME and the BRVO. If bevacizumab ophthalmic ONS-5010 is approved, Outlook Therapeutics plans to market it as the first and only ophthalmic formulation of bevacizumab approved by the FDA for use in the treatment of retinal disease in the United States, United Kingdom , Europe, Japan and other markets. Prospects Therapeutics plans to submit ophthalmic bevacizumab ONS-5010 to the US FDA as a new BLA under the PHSA 351 (a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

Forward-looking statements

This press release contains forward-looking statements. All statements other than statements of historical fact are “forward-looking statements”, “including those relating to future events. In some cases, you may identify forward-looking statements by terminology such as “intention,” “will,” “potential,” “may,” “might,” “should,” “wait,” “plan,” “anticipate, “” Project, “” believe, “” estimate, “” predict & CloseCurlyDoubleQuote; or “continue,” the negative of terms like these or other comparable terms, and other words or terms of similar meaning. These include, but are not limited to, statements relating to the completion of the public offering, the satisfaction of customary closing conditions related to the public offering and the intended use of the net proceeds of the public offering. Although Outlook Therapeutics believes it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations regarding future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its market and to the other conditions, operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include the risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission. These risks may cause actual results to differ materially from those expressed or implied by the forward-looking statements contained in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics assumes no obligation to update, modify or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable laws. applicable securities.


Media inquiries:

Harriet ullman

Deputy Vice President


Phone. : 617-669-3082

[email protected]

Investor inquiries:

Jenene thomas

Chief Executive Officer


T: 833.475.8247

[email protected]

Main logo

About Barbara J. Ross

Check Also

Certara Announces Completion of Public Offering of Ordinary Shares | New

PRINCETON, NJ, Nov. 22, 2021 (GLOBE NEWSWIRE) – Certara, Inc. (Nasdaq: CERT), a global leader …